[ibd-display-video id=3105496 width=50 float=left autostart=true] The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Idexx Laboratories is trading about 5% above a 173.11 entry from a consolidation .
The stock has a 92 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 92% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company reported 21% earnings-per-share growth. Revenue growth increased 14%, up from 10% in the prior report. The company has now posted rising growth in each of the last two reports.
Idexx Laboratories holds the No. 4 rank among its peers in the Medical-Systems/Equipment industry group. Cantel Medical ( CMD ) is the No. 1-ranked stock within the group.